Skip to main content
main-content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

Journal of Hematology & Oncology 1/2014

Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2014
Autoren:
Catarina Lundin, Erik Forestier, Mette Klarskov Andersen, Kirsi Autio, Gisela Barbany, Lucia Cavelier, Irina Golovleva, Sverre Heim, Kristiina Heinonen, Randi Hovland, Johann H Johannsson, Eigil Kjeldsen, Ann Nordgren, Lars Palmqvist, Bertil Johansson, the Swedish Cytogenetic Leukemia Study Group (SCLSG), the NOPHO Leukemia Cytogenetic Study Group (NLCSG)
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-8722-7-32) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CL and BJ designed the study, analyzed data, and wrote the article; EF provided critical comments on the design of the study, analysis, and of the interpretation of data; all authors supplied data, critically revised, and gave final approval of the article.

Background

It is well established that children with Down syndrome (DS) have an increased risk of developing acute leukemia, with a relative risk of approximately 20 and a cumulative risk of 2.1% at the age of 5 years [1, 2]. Acute lymphoblastic leukemia (ALL) in DS (DS-ALL) affects 1 in 300 children with this syndrome [2, 3] and several studies have shown that the outcome of DS-ALL is inferior to that of non-DS-ALL [46]. In fact, leukemia is one of the most common causes of death in individuals with DS, together with respiratory diseases, congenital circulatory defects, diseases of the digestive system, and Alzheimer’s disease [7]. The poor prognosis of DS-ALL has been attributed to a lower remission rate after induction therapy as well as to a higher degree of treatment-related toxicity [4, 811].
In contrast to myeloid leukemia in DS (ML-DS), which is associated with a transient myeloproliferative disorder (TMD), DS-ALL does not display any obvious preleukemic phase [12, 13]. Furthermore, specific genetic changes, such as GATA1 mutations in TMD and ML-DS that would possibly enable early diagnosis and treatment, seem to be rare in DS-ALL [14], although deregulation of the CRLF2 gene at Xp22.33/Yp11.32 is more prevalent in DS-ALL compared with non-DS-ALL, as are specific mutations in exon 16 of JAK2 at 9p24.1 [1518]. DS-ALL and non-DS-ALL have been reported to display similar median ages, gender distributions, and white blood cell (WBC) counts [13]. Thus, no clinical features, apart from the DS phenotype, at the time of diagnosis distinguish these two patient groups.
However, there are clear immunophenotypic differences between DS-ALL and non-DS-ALL, with mature B-cell ALL (Burkitt leukemia) and T-cell ALL being exceedingly rare in patients with DS; virtually all DS-ALL cases display a B-cell precursor (BCP) phenotype [11, 13, 1921]. As regards acquired genetic differences, although single nucleotide polymorphism (SNP) analyses have in general identified similar microdeletions in DS-ALL and non-DS-ALL cases [16, 2225], DS-ALL and non-DS-ALL are to a large extent cytogenetically distinct – DS-ALL are rarely high hyperdiploid (51–67 chromosomes) and seldom display MLL rearrangements or t(9;22)(q34;q11)/BCR-ABL1[5, 20, 26, 27]. The lack of specific ALL-associated gene fusions precludes risk group assignment and hence treatment stratification based on cytogenetics in most instances of DS-ALL.
In order to address further clinical and genetic differences between DS-ALL and non-DS-ALL and to identify prognostic factors in DS-ALL, we have ascertained and reviewed all pediatric ALL cases included in the Nordic Society of Pediatric Hematology, Oncology (NOPHO) registry 1981–2010.

Materials and methods

Patients

Between 1981 and 2010, a total of 128 childhood and adolescent (<18 years) DS-ALL cases were diagnosed in the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) and registered in the NOPHO database. A subset of the 128 patients (43 cases) was included in a recently reported retrospective, international study on DS-ALL [28]. Prior to 1992, some patients may have escaped registration due to a less developed database, but since 1992 data on clinical, immunophenotypic, and genetic features of all Nordic pediatric ALL cases, at least those <15 years of age, have been entered into the NOPHO register, which hence is all-inclusive and truly population-based for this age group since that time point. All DS patients had BCP ALL, and for this reason their clinical and genetic features were compared only with those of non-DS BCP ALL cases diagnosed during the same time period (n = 4,637). The 128 DS-ALL patients were treated according to five different protocols: NOPHO ALL-1981 (n = 19), NOPHO ALL-1986 (n = 21), NOPHO ALL-1992 (n = 42), NOPHO ALL-2000 (n = 34), and NOPHO ALL-2008 (n = 12). The corresponding distribution of the 4,637 non-DS-ALL patients was NOPHO ALL-1981 (n = 563), NOPHO ALL-1986 (n = 828), NOPHO ALL-1992 (n = 1,554), NOPHO ALL-2000 (n = 1,128), and NOPHO ALL-2008 (n = 564). Details on these protocols have been reported previously [29, 30]. The study was approved by the Regional Ethical Review Board at Lund University and informed consent was obtained according to the Declaration of Helsinki.

Genetic analyses

Chromosome banding analyses were performed using standard methods in 16 cytogenetic laboratories in the Nordic countries, and all abnormal karyotypes have been centrally reviewed each year since 1996 (Sweden)/2000 (all five Nordic countries) by the Swedish and the NOPHO Leukemia Cytogenetic Study Groups. Fluorescence in situ hybridization (FISH) or reverse-transcription polymerase chain reaction (RT-PCR) analyses were used to screen for the translocations/gene fusions t(1;19)(q23;p13) [TCF3/PBX1], t(9;22)(q34;q11) [BCR/ABL1], and t(12;21)(p13;q22) [ETV6/RUNX1], whereas FISH or Southern blot analyses were used to identify 11q23/MLL rearrangements. These targeted analyses have been performed prospectively from 1996 in Sweden and from 2000 in the other Nordic countries, with several additional cases prior to this time having been analyzed retrospectively. During recent years, various array analyses have also been increasingly used to establish and confirm the registered karyotypes. In the NOPHO ALL-2008 protocol, FISH-based screening for intrachromosomal amplification of chromosome 21 (iAMP21) was added to the targeted analyses. Detailed karyotypic data are given in Additional file 1: Table S1.

Statistical analysis

The PASW Statistics software for Windows (SPSS Inc., Chicago, IL) was used for all statistical analyses. The significance limit for two-sided P values was set to <0.05. Age, gender, WBC and platelet counts, types of event, and cytogenetic subgroups were compared within the DS-ALL group as well as between the 128 DS-ALL and the 4,637 non-DS-ALL cases using the chi square or the Mann–Whitney U tests with exact calculations of P values. Survival analyses were performed only on cases treated according to the NOPHO ALL-1992 and ALL-2000 protocols, partly because they were almost identical in risk stratification and treatment and partly because they comprised the majority of patients. The probabilities of event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan-Meier method and subgroups were compared using the Log rank test. In the analysis of EFS, events comprised induction failure, relapse, second malignant neoplasm (SMN), and death in complete remission 1 (DCR1). In the OS analyses, death of any cause was the end point. Patients in continuous complete remission 1 were followed between 0 and 355 months (median 134 months).

Results

Patients

The 128 DS-ALL patients comprised 2.7% of all 4,765 BCP ALL cases diagnosed and treated in the Nordic countries between 1981 and 2010, with the number of DS-ALL cases per year varying between 1 and 8 (median 5; P = 0.49) during this time period (Figure 1).
Within the DS-ALL cohort, there were no significant gender differences in age or WBC count distributions, whereas the platelet counts were higher in girls than in boys (median 47.0 × 109/l, range 5–359, and 26.5 × 109/l, range 4–493, respectively; P = 0.042). Age had no impact on the WBC and platelet counts.
The DS-ALL and non-DS-ALL patients did not differ as regards sex ratio (male/female: 1.03 and 1.11, respectively) and WBC counts (median 10 × 109/l, range 0.5-540, and 9 × 109/l, range 0.3-1670, respectively). The median age was 4 years in both groups; however, the age distributions varied significantly (Figure 2) – the age peaks were at 2 years in DS-ALL and 3 years in non-DS-ALL, and none of the DS patients had infant ALL (P = 0.029). The platelet counts were lower in DS-ALL than in non-DS-ALL (median 35 × 109/l; range 4–493, and 48 × 109/l; range 1–878; P = 0.005) (Table 1).
Table 1
Clinical features of the 128 DS-ALL and the 4,637 non-DS-ALL patients
Features
DS-ALL (%)
non-DS-ALL (%)
P valuea
Gender
   
 Female
63 (49)
2195 (47)
0.67b
 Male
65 (51)
2442 (53)
 
Age (years)
   
 <1
0 (0)
154 (3.3)
0.029 c
 1-9
95 (74)
3703 (80)
 
 10-17
33 (26)
780 (17)
 
WBC count (×10 9 /l)
   
 0-9
61 (48)
2408 (52)
0.51c
 10-49
50 (39)
1453 (31)
 
 >50
17 (13)
776 (17)
 
Platelet count (×10 9 /l) d
   
 <50
76 (59)
2310 (50)
0.005 c
 50-149
41 (32)
1473 (32)
 
 >150
6 (5)
755 (16)
 
EMD e
   
 CNS
5f (3.9)
125 (2.7)
NA
 Mediastinal
4f (3.1)
72 (1.6)
 
 Testis
0 (0)
15 (0.6)
 
CNS, central nervous system; DS-ALL, Down syndrome-related acute lymphoblastic leukemia; EMD, extramedullary disease; NA, not analyzed due to lack of EMD data in several instances; WBC, white blood cell.
aSignificant P values in bold type.
bChi square test.
cMann-Whitney U test.
dData on platelet counts missing in 5 DS-ALL and in 99 non-DS-ALL patients.
eData on CNS involvement missing in 16 non-DS-ALL patients, on mediastinal mass in one DS-ALL and in 51 non-DS-ALL patients, and on testicular involvement in 27 DS-ALL and in 990 non-DS-ALL patients.
fOne patient had CNS involvement as well as a mediastinal mass.

Genetic features

Informative karyotypes (normal or abnormal) at the time of diagnosis were available in 95 (74%) DS-ALL and in 3,283 (71%) non-DS-ALL cases (P = 0.43), with abnormal karyotypes being more common in non-DS-ALL (79%) than in DS-ALL (60%) (Table 2; P < 0.0001). The frequencies of normal and abnormal karyotypes in DS-ALL did not differ significantly between 1981–1995 (48% normal, 52% abnormal) and 1996–2010 (36% normal, 64% abnormal) (P = 0.36), whereas the proportions of karyotypic failures/missing data (1981–1995: 21% and 1996–2010: 4.7%) decreased significantly during the latter time period (P < 0.001). The corresponding frequencies in non-DS-ALL were 41% normal and 59% abnormal cases 1981–1995 and 14% normal and 86% abnormal cases 1996–2010 (P < 0.001), with the proportions of karyotypic failures/missing data being 53% for 1981–1995 and 10% for 1996–2010 (P < 0.001).
Table 2
Genetic features of the DS-ALL and the non-DS-ALL patients
Features
DS-ALL (%)
non-DS-ALL (%)
P valuea
Karyotype
   
 Abnormal
57 (60)
2581 (79)
<0.0001
 Normal
38 (40)
702 (21)
 
Modal number b
   
 Hypodiploidy
1 (1)
211 (6)
<0.0001
 Pseudodiploidy
37 (39)
940 (29)
 
 Hyperdiploidy
17 (18)
329 (10)
 
 High hyperdiploidy
2 (2)
1075 (33)
 
 >67 chromosomes
0 (0)
26 (1)
 
 Normal karyotype
38 (40)
702 (21)
 
TCF3 - PBX1 c
   
 Yes
1 (2.6)
70 (4.2)
1.00
 No
37 (97)
1592 (96)
 
BCR - ABL1 c
   
 Yes
1 (2.1)
73 (3.7)
1.00
 No
46 (98)
1923 (96)
 
MLL rearrangement c
   
 Yes
0 (0)
122 (7.6)
0.07
 No
41 (100)
1487 (92)
 
ETV6 - RUNX1 c
   
 Yes
8 (15)
568 (25)
0.11
 No
46 (85)
1719 (75)
 
t(8;14)(q11;q32)
   
 Yes
2 (2.1)
3 (0.09)
NA
 No
93 (98)
3280 (99.9)
 
iAMP21 d
   
 Yes
0 (0)
6 (1.1)
NA
 No
12 (100)
558 (98.9)
 
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; iAMP21, intrachromosomal amplification of chromosome 21; NA, not analyzed due to too few cases.
aChi square test. Significant P values in bold type.
bHypodiploidy was defined as <47 in DS and <46 in non-DS; pseudodiploidy as 47 in DS and 46 in non-DS; hyperdiploidy as 48–50 in DS and 47–50 in non-DS; and high hyperdiploidy as 51–67 chromosomes in both groups.
cBased only on informative cases, i.e., on which targeted molecular genetic or FISH analyses of these rearrangements had been performed.
dBased only on informative cases, i.e., on cases treated according to the ALL-2008 protocol and hence screened for iAMP21.
Among the DS-ALL patients, two (1.6%) had trisomy 21 mosaicism (the trisomic cells were involved in the leukemic clone), one (0.8%) had a Robertsonian translocation [der(14;21)(q10;q10)], and one (0.8%) had a complex constitutional unbalanced t(15;21;16) leading to gain of 21q; the remaining 124 (97%) patients had a classical non-mosaic trisomy 21. One patient had both DS and Klinefelter syndrome, i.e., a sex chromosome complement of XXY (Additional file 1: Table S1).
The most common acquired changes in DS-ALL were + X (14% of the 95 informative cases), deletions of 9p (13%; including some cases with microdeletions identified by array analyses), 12p (7%; including some cases with microdeletions identified by FISH and/or array analyses), 13q (6%; the majority identified by array analyses), and 1p (5%), +14/i(14)(q10) (5%), +17/i(17)(q10) (4%), and gain of an extra chromosome 21 (4%). The only recurrent translocations were t(12;21)(p13;q22), detected in 8 (15%) of the 54 cases analyzed by FISH and/or RT-PCR, and t(8;14)(q11;q32), found in two (2%) cases. The ALL-associated translocations t(1;19)(q23;p13) and t(9;22)(q34;q11) [with the P190 BCR/ABL1 transcript] were found in single cases; no DS-ALL harbored an 11q23/MLL rearrangement or an iAMP21. The distributions of modal numbers varied significantly between DS- and non-DS-ALL cases (P < 0.0001), with high hyperdiploidy (51–67 chromosomes) being found in two cases only (Table 2 and Additional file 1: Table S1). Although the frequencies of t(1;19), t(9;22), and t(12;21) were lower in the DS-ALL group, they did not differ significantly from the ones observed in non-DS-ALL. Cases with t(8;14) or iAMP21 were too few to allow meaningful statistical analyses (Table 2).

Survival of the DS-ALL patients in the NOPHO ALL-1992/2000 protocols

Of the 128 DS patients, 42 and 34 were treated according to the ALL-1992 and ALL-2000 protocols, respectively. There were no significant differences (P = 0.10) in 5-year EFS of the DS-ALL patients between these treatment regimens [pEFS 0.50 (standard error 0.077) vs. pEFS 0.67 (0.082)] or as regards 5-year OS (P = 0.31) [pOS 0.595 (0.076) vs. pOS 0.735 (0.085)]. Thus, these two protocols were combined in the subsequent survival analyses (Table 3). Within the DS-ALL cohort, gender, age and karyotype (abnormal vs. normal) had no impact on EFS or OS. The low number of ALL-associated translocations in DS-ALL precluded detailed analyses of their prognostic impact. However, it may be noteworthy that seven of the eight t(12;21)-positive DS-ALL patients remain in complete remission (Additional file 1: Table S1). There was a significant difference in 5-year EFS (P = 0.026) and in 5-year OS (P = 0.003) between DS-ALL patients with WBC counts below and above 50 × 109/l (Figure 3; Table 3).
Table 3
Survival of the DS-ALL patients treated according to the ALL-1992/2000 protocols in relation to clinical and genetic features
Features
5-year EFS (SE)
P valuea
5-year OS (SE)
P valuea
Gender
    
 Female
0.619 (0.080)
0.46
0.693 (0.078)
0.50
 Male
0.534 (0.080)
 
0.621 (0.081)
 
Age (years)
    
 0-4
0.479 (0.106)
0.88
0.632 (0.091)
0.77
 ≥5
0.558 (0.076)
 
0.668 (0.073)
 
WBC count (×10 9 /l)
    
 0-9
0.574 (0.086)
0.78
0.752 (0.076)
0.36
 ≥10
0.574 (0.077)
 
0.644 (0.074)
 
 0-49
0.610 (0.061)
0.026
0.747 (0.055)
0.003
 ≥50
0.364 (0.145)
 
0.364 (0.145)
 
Karyotype
    
 Abnormal
0.558 (0.076)
0.86
0.668 (0.073)
0.92
 Normal
0.468 (0.116)
 
0.661 (0.107)
 
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; EFS, event-free survival; OS, overall survival; SE, standard error; WBC, white blood cell.
aSignificant P values in bold type.

Survival differences between the DS-ALL and non-DS-ALL patients in the NOPHO ALL-1992/2000 protocols

Among the 4,637 non-DS-ALL patients, 1,554 and 1,128 were treated according to ALL-1992 and ALL-2000, respectively. There were no significant differences (P = 0.76) in 5-year EFS of the non-DS-ALL patients between these two protocols [pEFS 0.782 (0.010) vs. pEFS 0.785 (0.013)] or in 5-year OS (P = 0.51) [pOS 0.889 (0.008) vs. pOS 0.902 (0.009)]. These two protocols could hence be combined when comparing DS-ALL and non-DS-ALL.
The types of event varied significantly (P = 0.005) between the DS-ALL and non-DS-ALL cases, with induction failure being more common in DS-ALL and SMN being observed only among non-DS-ALL patients (Table 4). Nine DS-ALL patients had induction failure, of which 6 died due to toxicity (Table 4). The frequencies of induction failure did not differ between cases with WBC counts below or above 50 × 109/l (data not shown).
Table 4
Significant difference ( P= 0.005) a in types of event in DS-ALL and non-DS-ALL patients treated according to the ALL-1992/2000 protocols
Events
DS-ALL (% of events)
non-DS-ALL (% of events)
Relapse
23 (66)
507 (80)
Induction failure
9b (26)
47 (7.4)
DCR1
3 (8.6)
48 (7.6)
SMN
0 (0)
32 (5.0)
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; DCR1, death in complete remission 1; SMN, second malignant neoplasm.
aMann-Whitney U test.
bSix of the 9 patients with induction failure died due to toxicity.
When analysing the two treatment protocols together, both 5-year EFS and 5-year OS were significantly inferior in the DS-ALL cohort (Figure 4; Table 5).
Table 5
Comparison of survival data between the DS-ALL and non-DS-ALL patients treated according to the ALL-1992/2000 protocols
Protocol
5-year EFS (SE)
P valuea
5-year OS (SE)
P valuea
 DS-ALL
0.574 (0.057)
<0.001
0.691 (0.054)
<0.001
 non-DS-ALL
0.783 (0.008)
 
0.894 (0.006)
 
DS-ALL, Down syndrome-related acute lymphoblastic leukemia; EFS, event-free survival; OS, overall survival; SE, standard error.
aSignificant P values in bold type.

Discussion

The basic clinical features of this population-based DS-ALL patient cohort from the Nordic countries (Table 1) agree very well with previous studies on DS-ALL. For example, there were no infants, no case had mature B-cell leukemia or T-cell ALL, there were no differences between the DS-ALL and the non-DS-ALL patients in sex ratio, WBC counts, and median age at diagnosis, and the platelet counts were lower in DS-ALL [4, 8, 11, 13, 20, 26]. Thus, the present series is clearly representative of DS-ALL.
Since our study includes ALL cases diagnosed during the last three decades, it provides data pertinent to possible time-related aspects of diagnostic routines. We had anticipated that there could have been a bias as regards reporting DS-ALL cases to the registry during its early years, perhaps because some centres may have been less inclined to give intensive treatment to children with DS and/or to include them in the database. However, this was clearly not the case. The incidence of DS-ALL has been quite constant throughout the years, with no significant variation (Figure 1). Furthermore, we have no evidence that DS-ALL cases have been less well cytogenetically characterized through the years. In contrast, although karyotypic failures/missing data for DS-ALL were much more common 1981–1995 (21%) than between 1996 and 2010 (4.7%), the corresponding frequencies in non-DS-ALL were even higher (53% and 10%, respectively). This notwithstanding, whereas the proportion of abnormal karyotypes in DS-ALL has not increased greatly during the last few years, there has been a significant increase in the frequency of abnormal karyotypes in non-DS-ALL. We do not believe that this is due to technical advances in cytogenetic analyses only, which seem to have benefited non-DS-ALL more than DS-ALL, but rather to true biological differences.
As alluded to above, DS-ALL significantly less often displayed an abnormal karyotype (60%) compared with non-DS-ALL (79%) (Table 2). A similarly low frequency of clonal abnormalities (54%) was also noted in a previous collaborative, international cytogenetic study on acute leukemia in DS patients [26]. One reason for the higher proportion of normal karyotypes in DS-ALL could be that they more often harbor cytogenetically cryptic changes. In fact, deregulation of the CRLF2 gene, either through deletions of Xp22.33/Yp11.32 or by translocations between these regions and the immunoglobulin heavy chain locus (IGH@) at 14q32.33, both undetectable by conventional chromosome banding analysis, is substantially more common in DS-ALL than in non-DS-ALL [17, 18]. Furthermore, a “normal” karyotype in DS-ALL has an additional chromosome 21. Perhaps fewer additional, acquired aberrations are needed to establish the leukemia because of the presence of the “preleukaemic” trisomy 21, akin to what has been suggested for ML-DS, in which GATA1 mutations are only efficient in the context of +21c [31]. In fact, it has been demonstrated that trisomy 21 as such perturbs fetal lymphopoiesis [32].
In contrast to the study by Forestier et al.[26], in which it was reported that 11% of DS-ALL cases are high hyperdiploid, only 2% of the Nordic cases had a modal number between 51 and 67 chromosomes [27] (Table 2). The reason(s) for this pronounced difference is unclear. Although high hyperdiploid cells are notoriously difficult to culture in vitro and many cases may escape detection, masquerading as karyotypically normal or cytogenetic failures [33, 34], we deem it unlikely that the low frequency of such cases in our cohort is due to technical issues. First, the proportion of high hyperdiploid cases among the non-DS-ALL patients (33%) is on a par with other study groups [34]. Second, DNA index analyses of pediatric leukemias are performed in clinical routine, according to the NOPHO protocols, and they should have identified high hyperdiploid cases that were cytogenetically missed. Third, most laboratories in the Nordic countries use interphase FISH analyses to identify t(12;21) and all use FISH to screen for iAMP21. Since the vast majority of high hyperdiploid ALL have tetrasomy 21 [35], such analyses would also identify extra copies of chromosome 21 and hence suggest the presence of high hyperdiploidy. Furthermore, Heerema et al. [36] reported only four DS patients (0.8%) among 480 high hyperdiploid ALL cases. Thus, we believe that there may have been a bias in reporting high hyperdiploid DS-ALL cases in Forestier et al.[26].
Other ALL-associated abnormalities that were less common, but not significantly so, in DS-ALL were t(1;19), t(9;22), 11q23/MLL rearrangements, and t(12;21) (Table 2). However, the frequencies of t(1;19), t(9;22), and t(12;21) were slightly higher in this study compared with those reported in Forestier et al.[26]. This most likely reflects that targeted analyses for these abnormalities were performed in a larger proportion of Nordic DS-ALL cases. As regards iAMP21, this aberration has been actively screened for only in the ongoing NOPHO ALL-2008 protocol. So far, none of 12 DS-ALL cases treated according to this protocol has harbored an iAMP21 whereas it has been detected in 1% of non-DS-ALL cases (Table 2). The low frequency of iAMP21 in DS-ALL agrees well with data from UK MRC ALL97 [37]. The only structural abnormality that seems to be more common in DS-ALL is t(8;14)(q11;q32) (Table 2), something that has been noted also in several previous studies [3840]. Why most ALL-associated abnormalities are less frequent or, as regards t(8;14), more common in DS-ALL remain enigmatic.
The distribution of types of event differed significantly between the DS-ALL and non-DS-ALL patients (Table 4). The fact that induction failure was more common in the former group was not surprising; this has been repeatedly observed [4, 11, 41]. However, the lack of secondary malignant neoplasms (SMN) after treatment for DS-ALL is noteworthy – none of the 128 DS-ALL patients in the Nordic countries has developed SMN. Although not stressed in previous studies, this seems to be the case also in several other treatment trials, such as those from the Berlin-Frankfurt-Münster (BFM), Children's Cancer Group (CCG), and Italian Association of Pediatric Hematology and Oncology (AIEOP) groups [10, 11, 41, 42]. It is well known that individuals with DS in general have a lower incidence of solid tumors than non-DS-individuals [2], with possible explanations including gains of tumor suppressor genes on chromosome 21, impaired angiogenesis, and accelerated cell ageing [43]. Whether such mechanisms could be involved in preventing SMN in DS patients is unclear, not least considering that most SMN are not solid tumors but rather myelodysplastic syndromes and acute myeloid leukemia, with the latter being clearly overrepresented in DS as a de novo disease [2].
The only factor associated with survival in DS-ALL was the WBC count. Patients with a WBC count ≥50 × 109/l had significantly inferior 5-year EFS and 5-year OS compared with those with lower counts (Table 3; Figure 3). Although not surprising – a high WBC count is a well-established risk factor in pediatric non-DS-ALL [30] – this has not been clearly demonstrated in DS-ALL previously.
Data on improved outcome for DS-ALL have emerged during the last few years from some treatment trials [41, 42, 44], suggesting that induction and/or maintenance therapy has improved for this patient cohort. However, in the present study, both EFS and OS were still inferior for the DS-ALL cohort in the combined ALL-1992/2000 protocols (Figure 4; Table 5). Whether this depends on insufficient treatment intensity [45], clinical decision making for relapsed DS-ALL, or on treatment- and/or syndrome-related comorbidity [46] remains to be evaluated in detail.

Acknowledgements

This work was supported by the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, and the Swedish Research Council.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CL and BJ designed the study, analyzed data, and wrote the article; EF provided critical comments on the design of the study, analysis, and of the interpretation of data; all authors supplied data, critically revised, and gave final approval of the article.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
Additional file 1: Clinical and karyotypic data on the 128 DS-ALL patients.(DOC 186 KB)
13045_2014_392_MOESM1_ESM.doc
Authors’ original file for figure 1
13045_2014_392_MOESM2_ESM.pdf
Authors’ original file for figure 2
13045_2014_392_MOESM3_ESM.pdf
Authors’ original file for figure 3
13045_2014_392_MOESM4_ESM.pdf
Authors’ original file for figure 4
13045_2014_392_MOESM5_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Journal of Hematology & Oncology 1/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise